All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ZUMA 2: How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?

ZUMA 2: How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?

Wang reports on data from the ZUMA 2 trial. He comments on the effect that prior exposure to Bruton's tyrosine kinase (BTK) inhibitors can have in patients with relapsed/refractory mantle cell lymphoma (MCL) being treated with KTE-X19.

Share: